Publications 2024

Fernandez Salamanca M, Hompland T, Deręgowska-Cylke M, Van der Poel H, Bekers E, Guimaraes MAS, Lyng H, Van der Heide UA, Schoots IG, Van Houdt PJ (2024)
A DWI-based hypoxia model shows robustness in an external prostatectomy cohort
Front Oncol, 14, 1433197
DOI 10.3389/fonc.2024.1433197, PubMed 39109282

Marsilla J, Weiss J, Ye XY, Welch M, Milosevic M, Lyng H, Hompland T, Bruheim K, Tadic T, Haibe-Kains B, Han K (2024)
A T2-weighted MRI-based radiomic signature for disease-free survival in locally advanced cervical cancer following chemoradiation: An international, multicentre study
Radiother Oncol, 199, 110463
DOI 10.1016/j.radonc.2024.110463, PubMed 39067707

Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2024)
Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer
J Pathol, 264 (3), 270-283
DOI 10.1002/path.6344, PubMed 39329425

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Publications 2023

Leech M, Leijenaar RTH, Hompland T, Gaffney J, Lyng H, Marignol L (2023)
Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring
Anticancer Res, 43 (1), 351-357
DOI 10.21873/anticanres.16170, PubMed 36585179

Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
Cancers (Basel), 15 (18)
DOI 10.3390/cancers15184662, PubMed 37760629

Skingen VE, Hompland T, Fjeldbo CS, Salberg UB, Helgeland H, Ragnum HB, Aarnes EK, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2023)
Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels
Radiother Oncol, 188, 109875
DOI 10.1016/j.radonc.2023.109875, PubMed 37640161

Publications 2022

Lyng H, Skipar K, Hompland T (2022)
Targeted Therapy on the Screen: Do We Hit the Target?
Clin Cancer Res, 28 (24), 5233-5234
DOI 10.1158/1078-0432.CCR-22-2707, PubMed 36240006

Mo T, Brandal SHB, Köhn-Luque A, Engebraaten O, Kristensen VN, Fleischer T, Hompland T, Seierstad T (2022)
Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
Cancers (Basel), 14 (5)
DOI 10.3390/cancers14051326, PubMed 35267636

Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630

Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2022)
A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
Br J Cancer, 127 (2), 321-328
DOI 10.1038/s41416-022-01782-x, PubMed 35332267

Sinno N, Taylor E, Hompland T, Milosevic M, Jaffray DA, Coolens C (2022)
Incorporating cross-voxel exchange for the analysis of dynamic contrast-enhanced imaging data: pre-clinical results
Phys Med Biol, 67 (24)
DOI 10.1088/1361-6560/aca512, PubMed 36541560

Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
Radiother Oncol, 176, 17-24
DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778

Publications 2021

Hompland T, Fjeldbo CS, Lyng H (2021)
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030499, PubMed 33525508

Publications 2020

Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139

Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004

Publications 2018

Hompland T, Hole KH, Ragnum HB, Aarnes EK, Vlatkovic L, Lie AK, Patzke S, Brennhovd B, Seierstad T, Lyng H (2018)
Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients
Cancer Res, 78 (16), 4774-4785
DOI 10.1158/0008-5472.CAN-17-3806, PubMed 29945958

Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK (2018)
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790

Publications 2015

Lund KV, Simonsen TG, Hompland T, Kristensen GB, Rofstad EK (2015)
Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer
Radiother Oncol, 115 (3), 379-85
DOI 10.1016/j.radonc.2015.05.001, PubMed 25998804

Publications 2014

Hompland T, Ellingsen C, Galappathi K, Rofstad EK (2014)
DW-MRI in assessment of the hypoxic fraction, interstitial fluid pressure, and metastatic propensity of melanoma xenografts
BMC Cancer, 14, 92
DOI 10.1186/1471-2407-14-92, PubMed 24528854

Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501

Publications 2013

Ellingsen C, Hompland T, Galappathi K, Mathiesen B, Rofstad EK (2013)
DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts
Radiother Oncol, 110 (2), 335-41
DOI 10.1016/j.radonc.2013.10.018, PubMed 24231244

Ellingsen C, Walenta S, Hompland T, Mueller-Klieser W, Rofstad EK (2013)
The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI
Transl Oncol, 6 (5), 607-17
DOI 10.1593/tlo.13313, PubMed 24151541

Gaustad JV, Pozdniakova V, Hompland T, Simonsen TG, Rofstad EK (2013)
Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts
J Exp Clin Cancer Res, 32 (1), 93
DOI 10.1186/1756-9966-32-93, PubMed 24245934

Hompland T, Ellingsen C, Galappathi K, Rofstad EK (2013)
Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI
Acta Oncol, 53 (1), 6-15
DOI 10.3109/0284186X.2013.773073, PubMed 23445339

Publications 2012

Ellingsen C, Hompland T, Mathiesen B, Rofstad EK (2012)
Microenvironment-associated lymph node metastasis of human cervical carcinoma xenografts
Acta Oncol, 51 (4), 465-72
DOI 10.3109/0284186X.2011.636751, PubMed 22292610

Hompland T, Ellingsen C, Rofstad EK (2012)
Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure
BMC Cancer, 12, 544
DOI 10.1186/1471-2407-12-544, PubMed 23173554

Hompland T, Ellingsen C, Øvrebø KM, Rofstad EK (2012)
Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI
Cancer Res, 72 (19), 4899-908
DOI 10.1158/0008-5472.CAN-12-0903, PubMed 23027087

Hompland T, Gulliksrud K, Ellingsen C, Rofstad EK (2012)
Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights
Acta Oncol, 52 (3), 627-35
DOI 10.3109/0284186X.2012.737931, PubMed 23126523

Øvrebø KM, Ellingsen C, Hompland T, Rofstad EK (2012)
Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts
Acta Oncol, 52 (3), 604-11
DOI 10.3109/0284186X.2012.689851, PubMed 22671573

Publications 2011

Gulliksrud K, Hompland T, Galappathi K, Rofstad EK (2011)
Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging
Radiother Oncol, 101 (1), 217-22
DOI 10.1016/j.radonc.2011.06.036, PubMed 21840612

Øvrebø KM, Hompland T, Mathiesen B, Rofstad EK (2011)
Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging
Radiother Oncol, 102 (3), 429-35
DOI 10.1016/j.radonc.2011.11.013, PubMed 22197352

Publications 2008

Hompland T, Erikson A, Lindgren M, Lindmo T, de Lange Davies C (2008)
Second-harmonic generation in collagen as a potential cancer diagnostic parameter
J Biomed Opt, 13 (5), 054050
DOI 10.1117/1.2983664, PubMed 19021430

Publications 2007

Erikson A, Ortegren J, Hompland T, de Lange Davies C, Lindgren M (2007)
Quantification of the second-order nonlinear susceptibility of collagen I using a laser scanning microscope
J Biomed Opt, 12 (4), 044002
DOI 10.1117/1.2772311, PubMed 17867806